SMS Pharmaceuticals Limited (SMSPHARMA.BO)
INR 242.45
(2.08%)
INR 242.45
(2.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 370.89 Million INR | -70.11% |
| 2022 | 1.02 Billion INR | 4.08% |
| 2021 | 989.6 Million INR | 19.86% |
| 2020 | 825.61 Million INR | 19.07% |
| 2019 | 693.36 Million INR | 9.36% |
| 2018 | 633.99 Million INR | 1.22% |
| 2017 | 626.35 Million INR | 13.13% |
| 2016 | 553.65 Million INR | -61.28% |
| 2015 | 1.42 Billion INR | 14.66% |
| 2014 | 1.24 Billion INR | 17.48% |
| 2013 | 1.06 Billion INR | 11.95% |
| 2012 | 948.21 Million INR | 49.7% |
| 2011 | 633.4 Million INR | 29.04% |
| 2010 | 490.87 Million INR | 85.23% |
| 2009 | 265 Million INR | 4.66% |
| 2008 | 253.2 Million INR | 51.46% |
| 2007 | 167.18 Million INR | 27.25% |
| 2006 | 131.38 Million INR | -31.92% |
| 2005 | 192.98 Million INR | 15.44% |
| 2004 | 167.17 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 78.97 Million INR | -16.96% |
| 2023 Q1 | 289.68 Million INR | 5.69% |
| 2023 Q4 | 95.1 Million INR | -67.99% |
| 2023 FY | 307.86 Million INR | -70.11% |
| 2023 Q3 | 297.15 Million INR | -1.67% |
| 2023 Q2 | 302.19 Million INR | 4.32% |
| 2022 Q4 | 274.08 Million INR | 3.4% |
| 2022 FY | 1.02 Billion INR | 4.08% |
| 2022 Q1 | 253.39 Million INR | 25.12% |
| 2022 Q2 | 256.62 Million INR | 1.27% |
| 2022 Q3 | 265.07 Million INR | 3.29% |
| 2021 Q3 | 272.93 Million INR | 9.81% |
| 2021 FY | 989.6 Million INR | 19.86% |
| 2021 Q2 | 248.54 Million INR | -6.43% |
| 2021 Q1 | 265.61 Million INR | -0.03% |
| 2021 Q4 | 202.51 Million INR | -25.8% |
| 2020 Q1 | 169.23 Million INR | 8.1% |
| 2020 Q2 | 187.66 Million INR | 10.89% |
| 2020 FY | 825.61 Million INR | 19.07% |
| 2020 Q3 | 207.35 Million INR | 10.49% |
| 2020 Q4 | 265.69 Million INR | 28.13% |
| 2019 Q3 | 179.87 Million INR | 0.77% |
| 2019 FY | 693.36 Million INR | 9.36% |
| 2019 Q2 | 178.49 Million INR | 0.8% |
| 2019 Q1 | 177.08 Million INR | 22.79% |
| 2019 Q4 | 156.55 Million INR | -12.96% |
| 2018 Q1 | 154.56 Million INR | 0.0% |
| 2018 FY | 633.99 Million INR | 1.22% |
| 2018 Q4 | 144.21 Million INR | -10.6% |
| 2018 Q3 | 161.31 Million INR | -7.24% |
| 2018 Q2 | 173.91 Million INR | 12.52% |
| 2017 FY | 626.35 Million INR | 13.13% |
| 2016 FY | 553.65 Million INR | -61.28% |
| 2016 Q1 | 368.3 Million INR | -12.94% |
| 2016 Q2 | 373.11 Million INR | 1.31% |
| 2015 Q2 | 347.18 Million INR | 9.86% |
| 2015 FY | 1.42 Billion INR | 14.66% |
| 2015 Q4 | 423.06 Million INR | 26.58% |
| 2015 Q3 | 334.21 Million INR | -3.74% |
| 2015 Q1 | 316.03 Million INR | -28.03% |
| 2014 Q3 | 231.99 Million INR | -24.4% |
| 2014 Q2 | 306.87 Million INR | 14.01% |
| 2014 FY | 1.24 Billion INR | 17.48% |
| 2014 Q1 | 269.15 Million INR | -28.26% |
| 2014 Q4 | 439.1 Million INR | 89.28% |
| 2013 Q1 | 168.09 Million INR | -18.3% |
| 2013 Q4 | 375.19 Million INR | 48.11% |
| 2013 FY | 1.06 Billion INR | 11.95% |
| 2013 Q3 | 253.31 Million INR | -8.51% |
| 2013 Q2 | 276.86 Million INR | 64.71% |
| 2012 Q4 | 205.73 Million INR | 2.87% |
| 2012 Q1 | 190.66 Million INR | 1689.06% |
| 2012 Q2 | 218.51 Million INR | 14.61% |
| 2012 FY | 948.21 Million INR | 49.7% |
| 2012 Q3 | 200 Million INR | -8.47% |
| 2011 FY | 633.4 Million INR | 29.04% |
| 2011 Q4 | 10.65 Million INR | -93.58% |
| 2011 Q3 | 165.9 Million INR | 0.0% |
| 2010 FY | 490.87 Million INR | 85.23% |
| 2009 FY | 265 Million INR | 4.66% |
| 2008 FY | 253.2 Million INR | 51.46% |
| 2007 FY | 167.18 Million INR | 27.25% |
| 2006 FY | 131.38 Million INR | -31.92% |
| 2005 FY | 192.98 Million INR | 15.44% |
| 2004 FY | 167.17 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott India Limited | 5.98 Billion INR | 93.804% |
| Cipla Limited | 59.21 Billion INR | 99.374% |
| Gland Pharma Limited | 3.86 Billion INR | 90.395% |
| GlaxoSmithKline Pharmaceuticals Limited | 4.35 Billion INR | 91.488% |
| Kopran Limited | 859.54 Million INR | 56.85% |
| Marksans Pharma Limited | 3.28 Billion INR | 88.725% |
| NGL Fine-Chem Limited | 816.16 Million INR | 54.557% |
| Pfizer Limited | 4.33 Billion INR | 91.449% |
| Sanofi India Limited | 3.69 Billion INR | 89.957% |